QT-019C / Xiniao Biotechnology - LARVOL DELTA

UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Myositis • Systemic Lupus Erythematosus

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura • SELP

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Tianjin Huanhu Hospital

New P1 trial • CNS Disorders • Immunology • Multiple Sclerosis • Myasthenia Gravis • Neuromyelitis Optica Spectrum Disorder • Rare Diseases

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1 trial • ANCA Vasculitis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Thrombocytopenia • Vasculitis